Taiwan
· Delayed Price · Currency is TWD TaiGen Biopharmaceuticals Holdings Company Description
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide.
The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections.
Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibitor for the treatment of chronic hepatitis C; and Burixafor, a stem cell mobilizer which is in phase II clinical trial for stem cell transplantation and chemosenzitization.
In addition, the company is involved in the provision of consultation on pharmaceutical technology; and manufacture and sale of health food.
The company was founded in 2001 and is based in Taipei City, Taiwan.
| Country | Cayman Islands |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Kuo-Lung Huang |
Contact Details
Address: No. 138, Xinming Road Taipei, 11470 Taiwan | |
| Phone | 886 2 8177 7020 |
| Website | taigenbiotech.com.tw |
Stock Details
| Ticker Symbol | 4157 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | KYG866171005 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kuo-Lung Huang | Chairman of the Board, Chief Executive Officer, President and Chief Commercial Officer in Asia |
| Dr. Ming-Chu Hsu Ph.D. | Founder |
| Richard Lu | Vice President of Finance |
| Mark Kao | Head of the Accounting Department |
| Dr. Peter W. Tsao M.B.A., Ph.D. | Vice President Corporate Development |